Oyster Point Pharma Reports Second Quarter 2022 Financial Results and Recent Business Highlights
11.08.2022 - TYRVAYA (Varenicline Solution) Nasal Spray Achieved Net Product Revenue of $4.7 Million in Q2’22Approximately 30,000 TYRVAYA Prescriptions Filled During the Quarter, with Prescriptions Written by Over 5,700 Unique Eye Care Professionals; Launch to ...
Ji Xing United States Karen Castillo Paff Oyster Point Pharma Inc Ji Xing Pharmaceuticals Study Group
Source: wallstreet-online.de